-

PharmaEssentia Included in FTSE Russell Indices

TAIPEI--(BUSINESS WIRE)--PharmaEssentia Corporation, (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the company is included in the FTSE Global Equity Index Series, FTSE All-World Index, FTSE global All-Cap and total-Cap Indices, and the FTSE Global Mid Cap Index. These inclusions became effective after close of business on Friday, September 15, 2023.

Used extensively by institutional and retail investors globally, FTSE Russell is a global index leader and a wholly owned subsidiary of the London Stock Exchange Group.

About PharmaEssentia

PharmaEssentia (TPEx: 6446), headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.

For more information on PharmaEssentia Corporation, visit our website.

© 2023 PharmaEssentia Corporation. All rights reserved.

PharmaEssentia is a registered trademark of PharmaEssentia Corporation, and the PharmaEssentia logo is a trademark of PharmaEssentia Corporation.

 

Contacts

Media Contact:
Rachel Lipsitz, rachel_lipsitz@pharmaessentia.com

Industry:

PharmaEssentia Corporation

TSE:6446
Details
Headquarters: Taipei, Taiwan
CEO: Ko-Chung Lin
Employees: 600
Organization: PUB
Release Summary
PharmaEssentia Corporation today announced the company is included in FTSE Russell Indices.
Release Versions
English

Contacts

Media Contact:
Rachel Lipsitz, rachel_lipsitz@pharmaessentia.com

More News From PharmaEssentia Corporation

PharmaEssentia Announces Japan Approval of High-Dose Dosing Regimen for BESREMi®

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan with deep expertise in the development of novel biologics for hematology and oncology, and its Japanese subsidiary today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the inclusion of a high-dose dosing regimen for Ropeginterferon alfa-2b in the product label as an alternative dosing schedule. Clinical data show that the high...

PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Support Global Growth of BESREMi®

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan with deep expertise in the development of novel biologics for hematology and oncology, and its U.S. subsidiary PharmaEssentia USA Corporation today announced that the global corporate Board of Directors has approved an investment of approximately US$46 million to establish a new, wholly owned manufacturing subsidiary in Puerto Rico. The planned investment suppo...

PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET)

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the U.S. NCCN Clinical Practice Guidelines in Oncology have been updated to include ropeginterferon alfa-2b-njft as a Category 1 preferred treatment option for high-risk patients with esse...
Back to Newsroom